Prevalence and risk factors of diabetic peripheral neuropathy in a diabetics cohort: Register initiative “diabetes and nerves”

Abstract

ObjectiveThe aim of this study was to assess the prevalence of diabetic peripheral neuropathy (DPN) and associated risk factors among patients with type 1 (T1D) and type 2 diabetes (T2D). MethodsA total of 141 patients with T1D and 844 patients with T2D mostly from primary care practices were enrolled in our register initiative. DPN was assessed using the Neuropathy Symptom Score (NSS) and Neuropathy Deficit Score (NDS). Data were analyzed by bivariate and multivariate logistic regression. ResultsThe overall prevalence of DPN in the cohort was 40.3% [95% CI: 37.3-43.3%], 29.1% [22.0-36.9%] among patients with T1D and 42.2% [38.9-45.6%] with T2D (p<0.005). DPN prevalence increased with age from 11.9% [4.5-20.9%] aged ≤40 years up to >50% [47.7-57.5%] aged >70 years (p<0.001). The diabetes duration subclassification revealed a high DPN-prevalence of 35% [15.0-55.0%] among patients with T2D at time of diagnosis. A significant increase of prevalence was present 5 and 25 years following T1D and 25 years following T2D diagnosis (p<0.001). DPN risk factors were “older age” (OR [95% CI]: 1.05 [1.02-1.08], p<0.005) and loss of consciousness due to severe hypoglycemia episodes (OR [95% CI]: 10.28 [1.70-62.01], p<0.05) for T1D and “older age” (OR [95% CI]: 1.02 [1.00-1.04], p=0.056) and the presence of a cardiovascular-metabolic profile (obesity, hypertension, low HDL-c levels, elevated triglycerides, low physical activity and limited range of motion) for T2D. Furthermore, co-morbidities such as diabetic nephropathy (OR [95% CI]: 1.92 [1.14-3.22]), retinopathy (OR [95% CI]: 1.87 [1.10-3.18]) and peripheral artery disease (OR [95% CI]: 1.81 [1.07-3.08]) were independently associated with DPN (p<0.05). ConclusionsHigh rates of DPN among outpatients with diabetes suggest the need for early screening, especially in individuals that present with a plethora of co-morbidities. Diabetes treatment regimens that preclude a cardiovascular-metabolic risk profile and episodes of severe hypoglycemia should be sought, given that such episodes are more common among patients suffering from DPN.